REACH Study (MTN–034)

Links are provided to information about Reversing the Epidemic in Africa with Choices in HIV prevention (REACH), or MTN-034, a trial evaluating how adolescent girls and young women use the monthly dapivirine vaginal ring and oral Truvada® (FTC/TDF) as daily pre-exposure prophylaxis (PrEP). The Microbicide Trials Network is conducting this trial to gain a better understanding of the HIV prevention needs and preferences of adolescent girls and young women and to collect information on the safety of both approaches for women in these age groups.

External Links: 
Mirobicide Trials Network